Literature DB >> 26464693

Possibility of D2-40 as a diagnostic and tumor differentiation-suggestive marker for some of phosphaturic mesenchymal tumors.

Shogo Tajima1, Masashi Fukayama1.   

Abstract

Phosphaturic mesenchymal tumor (PMT) has been established as a tumor that causes tumor-induced osteomalacia (TIO) associated with mesenchymal neoplasm. Its lineage of differentiation has not been elucidated. Previously, the presence of lymphatic vessels inside PMTs has been documented using an anti-podoplanin antibody; the tumor cells of PMTs were reported to not react with it. In this study of 14 cases of PMTs, we used immunohistochemistry of D2-40, a relatively specific lymphatic endothelial marker, to see if they stained PMTs or not, with particular interest in its reaction with microcystic structures containing lymph-like fluid. We report that most of the PMTs (12 out of 14 cases; 86%) were immunostained by D2-40 in their tumor cells; D2-40-positive lymphatic vessels inside the tumor were also observed. We used a proportion score (0-4+), an intensity score (0-3+), and a total score (the sum of the proportion score and the intensity score) to quantitate our results. We report that 50% of cases (7 out of 14 cases) had a total score ≥ 4+; immunostaining of D2-40 in cases with a total score ≥ 4+ was easy to observe at a glance. Most of the tumor cells lining the microcystic structures were immunostained with D2-40. Thus, D2-40 could be a useful diagnostic marker of PMTs and it might also indicate that PMTs take a lymphatic endothelial immunophenotype.

Entities:  

Keywords:  D2-40; Phosphaturic mesenchymal tumor; immunohistochemistry

Mesh:

Substances:

Year:  2015        PMID: 26464693      PMCID: PMC4583925     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  13 in total

Review 1.  Lymphatic vessels are present in phosphaturic mesenchymal tumours.

Authors:  K Williams; A Flanagan; A Folpe; R Thakker; N A Athanasou
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

Review 2.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

Review 3.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23.

Authors:  Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Bone       Date:  2007-01-04       Impact factor: 4.398

4.  Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach.

Authors:  Evangelos Evangelou; Panayiotis A Kyzas; Thomas A Trikalinos
Journal:  Mod Pathol       Date:  2005-11       Impact factor: 7.842

5.  ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors.

Authors:  Shogo Tajima; Yuichi Takashi; Nobuaki Ito; Seiji Fukumoto; Masashi Fukuyama
Journal:  Med Mol Morphol       Date:  2015-06-30       Impact factor: 2.309

6.  Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas.

Authors:  Harriette J Kahn; Denis Bailey; Alexander Marks
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

7.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia.

Authors:  H Nakahama; T Nakanishi; H Uno; T Takaoka; N Taji; O Uyama; O Kitada; M Sugita; A Miyauchi; T Sugishita
Journal:  Urol Int       Date:  1995       Impact factor: 2.089

Review 8.  Fibroblast growth factor 23: state of the field and future directions.

Authors:  Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins
Journal:  Trends Endocrinol Metab       Date:  2012-08-24       Impact factor: 12.015

9.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

10.  Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung.

Authors:  M van de Rijn; C M Lombard; R V Rouse
Journal:  Am J Surg Pathol       Date:  1994-08       Impact factor: 6.394

View more
  5 in total

Review 1.  What is new about the molecular genetics in matrix-producing soft tissue tumors? -The contributions to pathogenetic understanding and diagnostic classification.

Authors:  Yu-Chien Kao; Jen-Chieh Lee; Hsuan-Ying Huang
Journal:  Virchows Arch       Date:  2019-11-07       Impact factor: 4.064

2.  Plasma soluble podoplanin is a novel marker for the diagnosis of tumor occurrence and metastasis.

Authors:  Xingpeng Zhao; Yanfang Pan; Weihua Ren; Fei Shen; Mengqiao Xu; Min Yu; Jianxin Fu; Lijun Xia; Changgeng Ruan; Yiming Zhao
Journal:  Cancer Sci       Date:  2018-01-19       Impact factor: 6.716

3.  The Foot That Broke Both Hips: A Case Report and Literature Review of Tumor-Induced Osteomalacia.

Authors:  Sara Beygi; Alfred Denio; Tarun S Sharma
Journal:  Case Rep Rheumatol       Date:  2017-09-14

Review 4.  Phosphaturic mesenchymal tumor and related wound problem.

Authors:  Xian Xiao; Xiaofang Sun; Pengwen Ni; Yao Huang; Ting Xie
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

5.  Phosphaturic mesenchymal tumors among elderly patients: a case report and review of literature.

Authors:  Zaina Adnan; David Nikomarov; Michal Weiler-Sagie; Noga Roguin Maor
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.